Antimicrobial resistance (AMR) is recognized around the world as a significant threat to global health and economic development. It is a major driver of death globally. By 2050, it is estimated that AMR will cause more deaths than cancer unless concerted treatment for multi-drug resistant TB (MDR-TB), only the third new anti-TB drug approved in the past half-century.

As a founding member of the AMR Industry Alliance (AMRIA), we are committed to partnering across the industry to collectively advance initiatives addressing AMR. AMRIA efforts span research and development, access, appropriate use and -up Fighting AMR via Responsible Manufacturing

We are a founding member of AMRIA and believe that partnering across the industry to collectively advance initiatives and practices is vital to fight AMR. Together with industry and academia, we have been able to advance on science-based approaches to help manage the impact of antimicrobial manufacturing.

As Viatris, we are compliant with AMRIA's Antibiotic Manufacturing Standard for our own operations and committed to implementing it across our external supply chain. All applicable Viatris manufacturing locations with antibiotic production have been internally assessed and adhere to AMRIA's Antibiotic Manufacturing Standard, including meeting the PNEC (RQ<1) as calculated by mass balance.

The Antibiotic Manufacturing Standard, facilitated by BSI Standards Limited (BSI), provides clear guidance to manufacturers in the global antibiotic supply chain to ensure that their antibiotics are made responsibly, helping to minimize the risk of AMR in the environment.

We are working on a phased approach with members of our external supply chain to assess suppliers' management and performance on the AMRIA Antibiotic Manufacturing Standard.

- Suppliers that do not fully adhere to the AMRIA standard develop and implement corrective actions.
- Viatris monitors these suppliers within established mitigation plans.

| • | In 2023, Viatris continued to conduct assessments at our top antibiotic suppliers with |
|---|--|
| | regard to the AMRIA standard according to our five-year plan. Since 2022, we have completed 30 supplier assessments. |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |